Cargando…

A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene carriers

BACKGROUND: Breast cancer is the most common female cancer worldwide. The lifetime risk of a woman being diagnosed with breast cancer is approximately 12.5%. For women who carry the deleterious mutation in either of the BRCA genes, BRCA1 or BRCA2, the risk of developing breast or ovarian cancer is s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guinan, Emer M, Hussey, Juliette, McGarrigle, Sarah A, Healy, Laura A, O’Sullivan, Jacintha N, Bennett, Kathleen, Connolly, Elizabeth M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618255/ https://www.ncbi.nlm.nih.gov/pubmed/23517070 http://dx.doi.org/10.1186/1471-2407-13-138

Ejemplares similares

Decision aids for female BRCA mutation carriers: a scoping review protocol
por: McGarrigle, Sarah A, et al.
Publicado: (2021)

Patient and family co-developed participant information to improve recruitment rates, retention, and patient understanding in the Rehabilitation Strategies Following Oesophago-gastric and Hepatopancreaticobiliary Cancer (ReStOre II) trial: Protocol for a study within a trial (SWAT)
por: O'Neill, Linda, et al.
Publicado: (2020)

Experience with Bilateral Risk-Reducing Mastectomy for an Unaffected BRCA Mutation Carrier
por: Maeshima, Yurina, et al.
Publicado: (2016)

Rehabilitation strategies following oesophagogastric and Hepatopancreaticobiliary cancer (ReStOre II): a protocol for a randomized controlled trial
por: O’Neill, Linda, et al.
Publicado: (2020)

Perspectives of Esophageal Cancer Survivors on Diagnosis, Treatment, and Recovery
por: Bennett, Annemarie E., et al.
Publicado: (2020)

ReStOre@Home: Feasibility study of a virtually delivered 12-week multidisciplinary rehabilitation programme for survivors of upper gastrointestinal (UGI) cancer - study protocol
por: O'Neill, Linda, et al.
Publicado: (2021)

Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers
por: Lee, Eun-Gyeong, et al.
Publicado: (2019)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
por: Osorio, A, et al.
Publicado: (2011)

Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female BRCA1 and BRCA2 Carriers: A Single Institution Experience in the Czech Republic
por: Zimovjanova, Martina, et al.
Publicado: (2023)

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
por: Silvestri, Valentina, et al.
Publicado: (2016)

'Pragmatic randomized controlled trial of individually prescribed exercise versus usual care in a heterogeneous cancer survivor population': A feasibility study PEACH Trial: Prescribed exercise after chemotherapy
por: Walsh, Julie M, et al.
Publicado: (2010)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
por: Osorio, A, et al.
Publicado: (2009)

Assessing Psychological Morbidity in Cancer-Unaffected BRCA1/2 Pathogenic Variant Carriers: A Systematic Review
por: Isselhard, Anna, et al.
Publicado: (2023)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Prostate screening uptake in Australian BRCA1 and BRCA2 carriers
por: McKinley, Joanne M, et al.
Publicado: (2007)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
por: Hakkaart, Christopher, et al.
Publicado: (2022)

Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers
por: Buckley, Kole H., et al.
Publicado: (2022)

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
por: Kadouri, L, et al.
Publicado: (2004)

Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
por: Evans, D. Gareth, et al.
Publicado: (2019)

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
por: Mulligan, Anna Marie, et al.
Publicado: (2011)

Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers
por: Vocka, Michal, et al.
Publicado: (2019)

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Rebbeck, Timothy R, et al.
Publicado: (2008)

Cancer risks among BRCA1 and BRCA2 mutation carriers
por: Levy-Lahad, E, et al.
Publicado: (2007)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers
por: Benitez-Buelga, Carlos, et al.
Publicado: (2016)

The presentation of metabolic dysfunction and the relationship with energy output in breast cancer survivors: a cross-sectional study
por: Guinan, Emer M, et al.
Publicado: (2013)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
por: Coignard, Juliette, et al.
Publicado: (2021)

Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay
por: Baert, Annelot, et al.
Publicado: (2017)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction
por: Tai, Yu Chuan, et al.
Publicado: (2008)

Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
por: Bougie, O., et al.
Publicado: (2011)

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI
por: Veltman, J., et al.
Publicado: (2008)

A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations: a pilot study
por: Dey, Shatovisha, et al.
Publicado: (2017)

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Odén, Lovisa, et al.
Publicado: (2016)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Management of the asymptomatic BRCA mutation carrier
por: Teller, Paige, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1tgg4jck732au2o56c79ghin7s